Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
185 GBX | +4.23% | -3.90% | -39.34% |
May. 22 | Transcript : Faron Pharmaceuticals Oy - Special Call | |
May. 20 | Faron Pharmaceuticals’ Blood Cancer Combo Shows Efficacy in Mid-stage Study | MT |
Sales 2024 * | 14.4M 15.62M | Sales 2025 * | 39.09M 42.39M | Capitalization | 156M 170M |
---|---|---|---|---|---|
Net income 2024 * | -6M -6.51M | Net income 2025 * | -4M -4.34M | EV / Sales 2024 * | 13 x |
Net Debt 2024 * | 30.6M 33.18M | Net cash position 2025 * | 42.27M 45.84M | EV / Sales 2025 * | 2.92 x |
P/E ratio 2024 * |
-7.08
x | P/E ratio 2025 * |
-14
x | Employees | 34 |
Yield 2024 * |
0.69% | Yield 2025 * |
-
| Free-Float | 60.71% |
Latest transcript on Faron Pharmaceuticals Oy
1 day | +4.23% | ||
1 week | -3.90% | ||
1 month | +23.33% | ||
3 months | +21.31% | ||
6 months | -32.48% | ||
Current year | -39.34% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 02-12-31 | |
Founder | 46 | 02-12-31 | |
Founder | 70 | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 02-12-31 | |
Chairman | 60 | 23-03-23 | |
Founder | 46 | 02-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 185 | +4.23% | 25,070 |
24-05-30 | 177.5 | -.--% | 5,038 |
24-05-29 | 177.5 | -1.39% | 6,947 |
24-05-28 | 180 | -6.49% | 32,067 |
24-05-24 | 192.5 | -1.79% | 89,782 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.34% | 169M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.67% | 12.27B |
- Stock Market
- Equities
- FARN Stock